Skip to main content
. 2018 Apr 16;36(16):1619–1627. doi: 10.1200/JCO.2017.76.5941

Fig 1.

Fig 1.

Model structure in 27 cost-effectiveness analyses this study identified: (A) did not consider clinicopathologic information at all (n = 2); (B) clinicopathologic information alone versus Oncotype DX (ODX) alone (n = 16); and (C) clinicopathologic information plus ODX versus clinicopathologic information alone (n = 9). AO, Adjuvant! Online; RS, recurrence score.